(Q21710717)

PubMed

7 February 2023

Eric R. Bates

2

Eric R

Bates

1 reference

PubMed

18657682

7 February 2023

Theodore A. Bass

series ordinal

3

author given names

Theodore A

author last names

Bass

1 reference

PubMed

18657682

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 February 2023

language of work or name

English

0 references

publication date

August 2008

0 references

published in

American Heart Journal

0 references

volume

156

0 references

issue

2

0 references

page(s)

16S-22S

0 references

1 reference

7 January 2021

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

1 reference

https://api.crossref.org/works/10.1016%2FJ.AHJ.2008.06.005

7 January 2021

10.1016/J.AHJ.2008.06.005

Identifiers

DOI

0 references